CLINICAL TRIAL: EFFECT OF TZD ON RESIDUAL BETA CELL FUNCTION IN IDDM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将确定吡格列酮对新诊断的1型糖尿病患者的胰岛素需求和糖尿病控制的影响。 吡格列酮是被批准用于治疗成人2型(非胰岛素依赖型)糖尿病的药物。吡格列酮可增强2型糖尿病患者的胰岛素治疗作用。研究表明，吡格列酮也会影响免疫细胞，尽管剂量要大得多。在1型糖尿病动物模型中，吡格列酮可延缓或预防糖尿病的发生或发展。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine the effect of Pioglitazone on insulin requirements and control of diabetes in patients with newly diagnosed type 1 diabetes. Pioglitazone is an approved drug for the treatment of type 2 (non-insulin dependent) diabetes in adults. Pioglitazone enhances the action of insulin therapy in patients with type 2 diabetes mellitus. Studies have shown that Pioglitazone also affects immune cells although in much bigger doses. In an animal model of type 1 diabetes, pioglitazone delays the onset or prevents the development of diabetes.